Kornimate/medical-research-clean huggingface dataset:
blood markers in adult patients with sudden sensorineural hearing loss (ssnhl)

Conditions: Idiopathic SSNHL; Age Over 18

Summary: the roles of thrombophilia and cardiovascular risk factors in sudden sensorineural hearing loss (ssnhl) remain controversial. cochlear micro-thrombosis has been hypothesized as a possible pathogenic mechanism of ssnhl. the objective was thus to measure the levels of markers of macrovascular thrombosis and microvascular risk factors

to recruit adult consecutive outpatients referred for ssnhl to the otolaryngologist clinic of our university hospital starting june 2016 and prospectively until december 31th 2018. plasma sampling and biomarkers quantification : after a 48-hours diet excluding serotonin- and tryptophan-rich food, fasting blood samples were collected into vacuum tubes containing 109 mm sodium citrate (becton-dickinson, le pont de claix, france) with a 9:1 blood-to-anticoagulant ratio. after removing 0.5 ml of whole blood for serotonin measurements, the remainder was centrifuged at 1,000 x g for 10 minutes, and the supernatant was then centrifuged at 3,000 x g for 15 minutes to isolate platelets and obtain platelet-poor plasma. importantly, the time between blood sampling and platelet/plasma isolation was less than one hour. aliquots of whole blood, platelets, and plasma were kept frozen (-20°c) until serotonin and homocysteine measurements performed within one week after congelation. whole blood, platelet and plasma 5-ht as well as plasma homocysteine (hcy) levels were measured by high pressure liquid chromatography coupled to fluorimetric detections . thrombophilia screening included measurements of antithrombin , protein c, protein s, factor v leiden, prothrombin g20210a, methylene tetrahydrofolate reductase (mthfr) c677t, antiphospholipid antibodies anticardiolipin igg and igm and anti-beta2 glycoprotein 1 igg), dilute russell viper venom time , rosner index, factor viii, von willebrand factor (vwf) activity and antigen. tests were performed on citrated plasma, serum or dna as appropriate and as previously described

Eligibility criteria:
inclusion criteria: * adult idiopathic ssnhl exclusion criteria: * secundary hearing loss

Keywords: sudden hearing loss, ssnhl serotonin homocystein antiphospholipid syndrom thrombophilia
efficacy of blue wavelength in managing dry eye

Conditions: Dry Eye Disease

Summary: the study is conducted to evaluate the efficacy of digital blue light blocking filter in improvement of clinical indices of dry eye and ocular symptoms related to dry eye. introduction: dry eye disease is a multifactorial disease of the ocular surface caused by loss of tear film homeostasis resulting damage to the ocular surface and neurosensory abnormalities.

60 subjects aged 20-35 years with ocular surface disease index score greater than 13 will be taken from the university of faisalabad. after taking consent, procedure starts from history then schirmer test 1 will be performed to measure the tear deficient dry eye. tear break up time will be done to assess the evaporative dry eye. corneal surface staining will be used to measure corneal erosions. osdi questionnaire will be used for the evaluation of ocular symptoms related to dry eye. the digital blue light blocking filter will be randomly installed in digital devices of the 80 subjects and rest of 80 will be without filter. after baseline data follow ups will be after 3 weeks and second after 8 weeks of filter use. schirmer test 1, tear break up time corneal surface staining and osdi will be performed on both groups (filter users and non-filter users) for the evaluation of dry eye. data will be analyzed using spss version 21. result of this study will give knowledge that use of digital blue light blocking filters are useful in the management of dry eye disease.

Eligibility criteria:
inclusion criteria: * females with age 20-35years * using digital devices androids and laptops * ametropia of up to 1.0 diopter sphere(ds) and astigmatism of less than 0.5 * emmetropes. exclusion criteria: * subjects using topical drugs * smokers * subjects undergoing dry eye treatment * history of contact lens wear within the past three months * corneal surface disease other than dry eye * corneal or eyelid infections * corneal surgeries * refractive error of more than 1 ds of se and astigmatism of greater than0.5dc * age \ 3 years * subjects already using blue light blocking filters * i phone users * pregnant women * males
treatment of venous thromboembolism in real-life patients

Conditions: Venous Thromboembolism

Summary: in a population of patients with venous thromboembolism and treated with oral anticoagulants (oac) in routine clinical practice in denmark this study will describe patients treated with each oac


Eligibility criteria:
inclusion criteria: 1. all patients ≥ 18 years diagnosed with incident vte at danish public hospitals from 2006 through 2015 2. first-time (index) vte will be defined as an in- or out-patient diagnosis of dvt or pe among patients redeeming a prescription for anticoagulant drugs within 30 days after index date exclusion criteria: 1. in the analyses on type and duration of anticoagulant use, patients with cancer will be excluded as they typically receive low molecular heparin directly from the hospital and their use of anticoagulants can therefore not be captured by redeemed prescriptions at pharmacies.
assessments of sarcopenia prevalence in chronic heart failure patients and in subjects before tavi

Conditions: Sarcopenia; Chronic Heart Failure

Summary: the main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation. the loss of muscle mass in chronic heart failure patients is a prognostic factor for sarcopenia. the purpose was to identify in these patients signs of sarcopenia for a better management.

age-related muscle loss, termed sarcopenia, affects 10% of elderly subjects aged 60-70 years and more than 30% above the age of 80. the concept of sarcopenia has been supported by the recent findings of muscular atrophy which was related to the decrease of protein synthesis because of the "anabolic resistance", affecting the muscular fibers type ii. in fact, sarcopenia could be a consequence of chronic disease and not only an issue in the elderly people. the diagnosis is assessed by the weak muscle mass and the muscle strength and function. a description of these muscle parameters has been described in a study of 200 patients with nyha class ii-iii and showed that 19,5 % have a decrease in muscle mass. they also showed that these patients have a lower functional ability. these findings prompted us to investigate the prevalence of sarcopenia in chronic heart failure subjects for a better management of these patients.

Eligibility criteria:
inclusion criteria: * major patients (\>18 years) * men or women * hospitalized in pre- trans aortic valvular implantation assessment in the cardiology department of the university hospital centre of clermont-ferrand or * patients with chronic heart failure in charge in the hospital of clermont-ferrand or convalescence in the pneumocardiological clinic of durtol exclusion criteria: * patient not affiliated to social security * inability to understand the information consent letter * not having signed informed consent * has a mental or legal incapacitation and is unable to provide informed consent.

Keywords: sarcopenia heart failure (hf) the trans aortic valvular implantation (tavi)
study to evaluate the efficacy and safety of my008211a in subjects with primary immunoglobulin a nephropathy (igan)

Conditions: IgA Nephropathy (IgAN)

Summary: efficacy and safety of my008211a in igan patients

this was a multicenter, randomized, double-blind, dose-ranging, parallel-group study. two doses of my008211a (200mg, 400mg) were compared with placebo. the study comprised a screening period of this study for 90 days, an efficacy observation period for 24 weeks, a long-term study for 80 weeks, and a follow-up period for 2 weeks.

Eligibility criteria:
inclusion criteria: 1. males or females ≥ 18 and ≤ 75 years of age at screening. 2. estimated gfr(egfr) ≥30 ml/min/1.73m2. 3. subjects with a biopsy-confirmed diagnosis of igan. 4. urine protein ≥0.75 g/24h from a 24h urine collection. 5. all patients must have been on stable supportive care including a maximally tolerated dose or approved maximal dose of acei or arb therapy for at least 90 days prior to the first administration of study drug. 6. subjects who received sglt2i must have been on a stable treatment with the maximum allowed or tolerated dose prior to the first administration of study drug. 7. vaccination against neisseria meningitidis(menacwy) is required within 3 years. 8. vaccination for the prevention of s. pneumoniae is required within 5 years. exclusion criteria: 1. systolic blood pressure \>130 mm hg or diastolic blood pressure \>80 mm hg. 2. presence of any secondary igan. 3. presence of rapidly progressive glomerulonephritis. 4. presence of other chronic kidney diseases. 5. patients with a diagnosis of type 1 or type 2 diabetes mellitus. 6. a history of invasive infections caused by encapsulated bacteria, e.g., meningococci or pneumococci. 7. patients previously treated with immunosuppressive agents exposure within 90 days prior to start of study drug dosing. 8. patients previously treated with traditional chinese medicine containing immunosuppressive ingredients within 90 days prior to start of study drug dosing. 9. patients who had been treated with any systemic corticosteroids within the 180 days before treatment ≥20 mg/d for primary igan indication. 10. patients who previously have received biologic agent or monoclonal antibodies prior to start of study drug dosing within 5 half-lives or 30 days (whichever is longer). 11. patients who have received live/attenuated vaccines within the 4 weeks prior to randomization, or plan to receive during the trial.

Keywords: kidney disease primary glomerular disease
peak flow monitoring in older adults with asthma

Conditions: Asthma

Summary: evaluate the incremental effectiveness of peak flow monitoring ove symptom monitoring as a management tool to enhance asthma control in adults \>= 50 years with moderate-severe asthma.

background: we propose a five-year demonstration and education project to assess the incremental value of peak flow monitoring (pfm) over symptom monitoring (sm) as a management tool for asthma control in adults greater than or equal to 50 years with moderate-severe asthma. we will develop three parallel asthma education programs for older adults using as our base an existing asthma education program (air/kaiser adult education program) of demonstrated efficacy for adults ,50 years of age. design narrative: primary outcome frequency and cost of health care utilization for asthma, and asthma-specific quality of life key secondary outcomes prebronchodilator fev1; diurnal variability in pef the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
inclusions: doctor-diagnosed asthma; \>=50 years; using asthma medications; \>12% increase in fev1 after two puffs of inhaled beta-agonist; willing to participate in asthma meducation program and two-year follow up; likely to stay in portland area; kpnw member for two years. exclusions: unable to read, speak or understand english; no telephone; failure to keep two pre-randomization appointments; inability to reproducible fev 1 maneuver; participation in pilot phase of study; concurrent participation in any other medical research study.
sperm selection and embryo development: comparison of the density gradient centrifugation and microfluidic chip sperm preparation methods sperm selection and embryo development: comparison of the density gradient centrifugation and microfluidic chip sperm preparation methods

Conditions: Reduced Sperm Motility; IVF; ICSI; Astheno Teratozoospermia

Summary: purpose: to compare the effects of the density gradient centrifugation and microfluidic chip sperm preparation methods on embryo development in a study population with astheno-teratozoospermia. materials and methods: in this prospective study, the semen samples of the patients with astheno-teratozoospermia were divided into two groups for preparation with either the microfluidic or density gradient methods. selected spermatozoa were used to fertilize the mature sibling oocytes. semen parameters and embryo development on days 3 and 5 were assessed.


Eligibility criteria:
inclusion criteria: * infertile men with astheno-teratozoospermia * women were aged from 18 to 39 * women had at least two mature oocytes. exclusion criteria: * mi oocytes

Keywords: sperm ivf icsi abnormal morphology of sperm astheno teratozoospermia microfluidic chip
comparison efficacy of 14-day triple therapy: clarithromycin vs. levofloxacin on eradication of h. pylori

Conditions: Helicobacter Pylori Gastrointestinal Tract Infection

Summary: comparison efficacy of 14-day triple therapy between clarithromycin and levofloxacin on the eradication of helicobacter pylori in syrian population


Eligibility criteria:
inclusion criteria: 1-patients are aged greater than 18 years old who have h. pylori infection diagnosed by any of following three methods: i-positive rapid urease test (clotest). ii-histologic evidence of h. pylori by modified giemsa staining. iii-positive 13c-urea breath test. without prior eradication therapy and are willing to receive therapy. exclusion criteria: 1. children and teenagers aged less than 18 years. 2. previous eradication treatment for h. pylori. 3. patients who took any drug, which could influence the study results such as proton pump inhibitor, h2 blocker, mucosal protective agent and antibiotics. 4. history of gastrectomy. 5. gastric malignancy, including adenocarcinoma and lymphoma, 6. previous allergic reaction to antibiotics (amoxicillin, clarithromycin, levofloxacin) and prompt pump inhibitors (es-omeprazole). 7. contraindication to treatment drugs. 8. pregnant or lactating women. 9. severe concurrent disease. 10. liver cirrhosis. 11. chronic kidney disease. 12. patients who cannot give informed consent by himself or herself.

Keywords: helicobacter pylori helicobacter infections proton pump inhibitors
self-proning and repositioning in covid-19 outpatients at risk of complicated illness

Conditions: COVID-19; COVID-19 Pneumonia; Proning; Hospitalization; Death; Outpatient; Complication

Summary: the rapid development of safe and effective covid-19 treatment is a global health priority. numerous studies evaluating therapies for this disease are currently underway, but the majority of these are in hospitalized patients with severe illness. consequently, there is an urgent need to identify therapies that prevent mild covid-19 cases in the community from becoming more severe. "proning" or lying face down in bed has been shown to improve breathing and oxygen levels in covid-19 patients, reducing the need for breathing tubes and ventilators and increasing survival. the current study will investigate whether proning and repositioning (lying on one's side or sitting up) can prevent mild cases of covid-19 from becoming more severe resulting in fewer hospitalizations and death. a randomized controlled trial will be used to reduce the risk of bias when testing this intervention. unvaccinated or partially vaccinated adult patients with a positive covid-19 test willing to participate and well enough to be treated outside the hospital will be randomly assigned to one of two groups: a home-proning intervention group with instructions and daily reminders to prone and reposition during the day and at night, and a standard care group. our goal is to assess whether home-proning/repositioning leads to fewer hospitalizations and death when compared with standard care. we'll also compare recovery time, use of antibiotics and follow up emergency department visits between these two groups. the current pilot study will assess the feasibility of a larger investigation or "main trial", meaning it will be small scale test of methods and procedures to be used on a larger scale.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years 2. positive sars-cov-2 pcr test 3. presence of two or more of the following criteria: 1. age\>55 years 2. fever by history or at presentation 3. cough 4. dyspnea/shortness of breath 5. fatigue necessitating daytime bed rest 6. one or more of the following medical conditions: * hypertension * diabetes * cardiovascular disease * chronic lung disease * chronic kidney disease * obesity (bmi≥30kg/m2) 7. tachycardia \> 110 bpm 8. oxygen saturation \<94% 9. one or more of the following laboratory abnormalities: * lymphocytes \<1500/microl * esr \> 100 mm/h * crp \> 10 mg/l * d-dimer \> 1000 ng/ml * ldh \> 240 u/l 10. bilateral infiltrates or ground glass opacities on chest x-ray or ct scan 4. socially and medically fit for discharge 5. access to a smartphone exclusion criteria: 1. pregnancy \>20/40 weeks 2. body mass index (bmi) \>40 kg/m2. 3. skeletal deformities that interfere with proning 4. developmental delay or cognitive impairment that would preclude patient cooperation 5. other contraindications to proning including any of the following: recent abdominal surgery, active vomiting, acute intoxication. 6. unlikely to adhere to the proning protocol according to the treating physician's judgment 7. fully vaccinated for covid-19
characterization of the mechanisms of resistance to azacitidine

Conditions: Myelodysplastic Syndromes or Acute Myeloid Leukemia With Multilineage Dysplasia

Summary: myelodysplastic syndromes (mds) are frequent diseases in elderly patients (median age: 71 years). ipss classification defines low risk (low and intermediate 1), and high risk (intermediate 2 and high) mds. high-risk mds (mds-hr) have a high risk of transformation into acute leukemia with multilineage dysplasia (aml-dml). the success of azacitidine has been mainly achieved through a rigorous empirical and clinical research, but the molecular mechanisms by which this molecule exerts its effects remain poorly characterized. the primary mode of action of azacytidine is through dna demethylation, and integration in to mrna that favor traduction inhibition. the impact of this molecule on various cell death programs involved in the elimination of leukemic cells : apoptosis and autophagy is currently poorly known. the research program and clinical studies we proposed focus on two major aspects: - main objective: molecular mechanism of action and resistance to azacitidine: role of apoptosis versus autophagy. - secondary objective: reversion of azacytidine resistance using different drugs targeting apoptosis and/or autophagy. our laboratory has identified new molecules to selectively induce different types of cell death (apoptosis or autophagy).


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * high risk or intermediate 2 mds (ipss) * aml-md (who classification) * treatment with minimum three to six cycles of azacitidine * informed consent form signed exclusion criteria: * treatment with others chemotherapies alone or in association
efficacy of short-course blinatumomab for mrd erradication in b-all

Conditions: Acute Lymphoblastic Leukemia; Measurable Residual Disease (MRD)

Summary: detectable measurable residual disease (mrd) is the most important prognostic factor for b-cell acute lymphoblastic leukemia (b-all) for overall survival (os) and disease-free survival (dfs). patients who are mrd positive and have no access to novel immunotherapies should receive an allogeneic hematopoietic stem cell transplantation (hsct). blinatumomab is considered a standard of care (soc) for this group of patients, however, the ideal treatment dose for mrd is unknown as doses were adjusted from the relapsed/refractory setting. preliminary data suggest short cycles of blinatumomab can also be effective in states of lower disease burden prior to transplant. thus, the investigators are performing a phase 2 trial assessing 7 days of blinatumomab as a bridge to hsct primary endpoint is assessing the mrd response following a short-course blinatumomab infusion in patients with b-all with complete response (cr) and have detectable mrd disease who are candidates for hsct. secondary endpoints include incidence of adverse events, os, dfs, percentage of patients who receive hsct, incidence of cytokine release syndrome (crs) and immune effector cell associated neurotoxicity syndrome (icans)

during the proposed treatment, blinatumomab therapy will be assigned as follows: blinatumomab 17.5 mcg per day for 2 days, followed by blinatumomab 28 mcg per day for 5 days. dexamethasone 20 mg will be applied one hour before starting dose. the immunotherapy will be applied as a 24-hour continuous infusion. the scheduled appointments will be on the initial day of blinatumomab, when the patient will be discharged from hospital and evaluation will be performed on day 10 with bone marrow aspiration and mrd assessment trough next generation flow cytometry. the results will be given at the appointment on day 14, along with an assessment profile for hsct.

Eligibility criteria:
inclusion criteria: * philadelphia chromosome-negative b-cell acute lymphoblastic leukemia * mrd detectable in complete response (above the limit of quantification according to fcm) * performance status 0-2 on the ecog scale * no prior organ damage * having a potential related or unrelated donor exclusion criteria: * performance status on the ecog scale \>2 * hct-ci \>3 points * patients who do not wish to participate in clinical study. * active central nervous system infiltration (cns3) * active extramedullary disease * having previously received blinatumomab * absence of related or unrelated donors

Keywords: blinatumomab measurable residual disease